Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Irritable Bowel Syndrome(2025)
-
摘要: 肠易激综合征是一种临床常见病，其患病率较高且具有较强的复发性。为帮助临床医师对肠易激综合征进行准确、合理的诊断与治疗，本共识旨在明确肠易激综合征的定义、流行病学特征、病因与发病机制、诊断标准及治疗方法，以提升对肠易激综合征的认识，规范临床诊断和治疗行为。Abstract: Irritable bowel syndrome is a common clinical disease with a high incidence and strong recurrence. To assist clinical physicians in accurately and reasonably diagnosing and treating gallstones, this consensus starts with the understanding, diagnosis, and treatment of irritable bowel syndrome in traditional Chinese medicine and Western medicine, comprehensively and deeply introducing the recent research progress of gallstones, highlighting clinical practicality.
-
-
[1] Lacy BE, Mearin F, Chang L, et al. Bowel disorders[J]. Gastroenterology, 2016, 150: 1393-1407. doi: 10.1053/j.gastro.2016.02.031
[2] 潘国宗, 鲁素彩, 柯美云, 等. 北京地区肠易激综合征的流行病学研究: 一个整群、分层、随机的调查[J]. 中华流行病学杂志, 2000, 21(1): 26-28.
[3] 熊理守, 陈旻湖, 陈惠新, 等. 广东省社区人群肠易激综合征的流行病学研究[J]. 中华医学杂志, 2004, 84(4): 278-281. doi: 10.3760/j:issn:0376-2491.2004.04.005
[4] Xiong LS, Chen MH, Chen HX, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling[J]. Aliment Pharmacol Ther, 2004, 19(11): 1217-1224. doi: 10.1111/j.1365-2036.2004.01939.x
[5] Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study[J]. Gastroenterology, 2021, 160(1): 99-114. doi: 10.1053/j.gastro.2020.04.014
[6] 张璐, 段丽萍, 刘懿萱, 等. 中国人群肠易激综合征患病率和相关危险因素的Meta分析[J]. 中华内科杂志, 2014, 53(12): 969-975. doi: 10.3760/cma.j.issn.0578-1426.2014.12.011
[7] 谷诺诺, 王凯星, 杨倩, 等. 李佃贵教授基于浊毒理论治疗肠易激综合征经验[J]. 四川中医, 2017, 35(6): 3-5.
[8] 陈婷, 唐旭东, 王凤云, 等. 腹泻型肠易激综合征中医辨证的源流及发展趋势[J]. 中华中医药杂志, 2015, 30(8): 2671-2674.
[9] 黄绍刚, 林仰锦. 从五脏相关角度探讨肠易激综合征核心病机[J]. 中国中医基础医学杂志, 2013, 19(3): 243-245.
[10] Yao X, Yang YS, Cui LH, et al. The overlap of upper functional gastrointestinal disorders with irritable bowel syndrome in Chinese outpatients: A multicenter study[J]. J Gastroenterol Hepatol, 2016, 31(9): 1584-1593. doi: 10.1111/jgh.13317
[11] De Bortoli N, Tolone S, Frazzoni M, et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders[J]. Ann Gastroenterol, 2018, 31(6): 639-648.
[12] Simrén M, Törnblom H, Palsson OS, et al. Management of the multiple symptoms of irritable bowel syndrome[J]. Lancet Gastroenterol Hepatol, 2017, 2(2): 112-122. doi: 10.1016/S2468-1253(16)30116-9
[13] Shiha MG, Aziz I. Review article: Physical and psychological comorbidities associated with irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2021, 54 Suppl 1: S12-S23.
[14] Pinto-Sanchez MI, Ford AC, Avila CA, et al. Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency[J]. Am J Gastroenterol, 2015, 110(7): 1038-1048. doi: 10.1038/ajg.2015.128
[15] Drossman DA, Hasler WL. RomeⅣ: functional GI disorders: disorders of gut-brain interaction[J]. Gastroenterology, 2016, 150(6): 1257-1261. doi: 10.1053/j.gastro.2016.03.035
[16] 王伟岸, 钱家鸣, 潘国宗. 肠易激综合症的诊断标准和鉴别诊断[J]. 胃肠病学和肝病学杂志, 2001, 10(2): 106-109.
[17] Camilleri M. Diagnosis and treatment of irritable bowel syndrome: a review[J]. JAMA, 2021, 325(9): 865-877.
[18] Bai T, Xia J, Jiang Y, et al. Comparison of the Rome Ⅳ and Rome Ⅲ criteria for IBS diagnosis: A cross-sectional survey[J]. J Gastroenterol Hepatol, 2017, 32(5): 1018-1025.
[19] Wang B, Zhao W, Zhao C, et al. What impact do RomeⅣ criteria have on patients with IBS in China?[J]. Scandinavian J Gastroenterol, 2019, 54(12): 1433-1440.
[20] Aziz I, Törnblom H, Palsson OS, et al. How the change in IBS criteria from Rome Ⅲ to Rome Ⅳ impacts on clinical characteristics and key pathophysiological factors[J]. Am J Gastroenterol, 2018, 113(7): 1017-1025.
[21] Ghoshal UC, Gwee KA, Chen M, et al. Development, translation and validation of enhanced asian RomeⅢquestionnaires for diagnosis of functional bowel diseases in major asian languages: a Rome Foundation-Asian Neurogastroenterology and Motility Association Working Team Report[J]. Neurogastroenterol Motil, 2015, 21(1): 83.
[22] 中华医学会消化病学分会胃肠功能性疾病协作组, 中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J]. 中华消化杂志, 2020, 40(12): 803-818.
[23] Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time[J]. Scand J Gastroenterol, 1997, 32(9): 920-924.
[24] 中华中医药学会脾胃病分会. 肠易激综合征中医诊疗专家共识(2024)[J]. 中医杂志, 2024, 65(18): 1948-1956.
[25] Dhaliwal SK, Hunt RH. Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective[J]. Eur J Gastroenterol Hepatol, 2004, 16(11): 1161-1166.
[26] Ilnyckyj A, Graff LA, Blanchard JF, et al. Therapeutic value of a gastroenterology consultation in irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2003, 17(7): 871-880.
[27] Schumann D, Klose P, Lauche R, et al. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis[J]. Nutrition, 2018, 45: 24-31.
[28] Maleki BH, Tartibian B, Mooren FC, et al. Low-to-moderate intensity aerobic exercise training modulates irritable bowel syndrome through antioxidative and inflammatory mechanisms in women: results of a randomized controlled trial[J]. Cytokine, 2018, 102: 18-25.
[29] Johannesson E, Ringström G, Abrahamsson H, et al. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects[J]. World J Gastroenterol, 2015, 21(2): 600.
[30] 姚思杰, 王栩芮, 张明明. 痛泻要方对肝郁脾虚型IBS-D患者的临床疗效及其机制[J]. 中国实验方剂学杂志, 2020, 26(12): 107-113.
[31] Tang X, Lu B, Li Z, et al. Therapeutic Effect of Chang'an Ⅰ Recipe(肠安Ⅰ号方)on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial[J]. Chin J Integr Med, 2018, 24(9): 645-652.
[32] Tang X, Zhang S, Hou X, et al. Post-marketing Re-evaluation of tongxiening granules(痛泻宁颗粒)in treatment of diarrhea-predominant irritable bowel syndrome: a multi-center, randomized, double-blind, double-dummy and positive control trial[J]. Chin J Integr Med, 2019, 25(12): 887-894.
[33] 郝云龙, 童昌珍. 舒肝解郁胶囊治疗肠易激综合征合并抑郁症的疗效观察[J]. 临床消化病杂志, 2014, 26(6): 340-342.
[34] 王静宇, 李树华, 高玉肖. 参苓白术散对腹泻型肠易激综合征脾虚湿盛证的疗效[J]. 深圳中西医结合杂志, 2022, 32(1): 74-76.
[35] 周燕. 醒脾祛湿饮治疗腹泻型肠易激综合征(脾虚湿盛型)的临床研究[J]. 中西医结合心血管病电子杂志, 2017, 5(33): 122-122.
[36] 李倩, 蒋军林. 参苓白术颗粒治疗腹泻型肠易激综合征80例临床观察[J]. 中医药导报, 2013, 19(5): 41-42.
[37] 叶蜀晖. 四神丸合附子理中丸治疗腹泻型肠易激综合征62例[J]. 山东中医杂志, 2010, 29(5): 310-310.
[38] 王宝迎, 杨明会. 健脾温肾法治疗脾肾阳虚型腹泻型肠易激综合征疗效观察[J]. 山西中医, 2017, 33(2): 48-51.
[39] 李锦伟, 丁志钦, 金立, 等. 固本益肠片联合复方谷氨酰胺和曲美布汀治疗肠易激综合征的临床研究[J]. 现代药物与临床, 2017, 32(1): 63-66.
[40] 左云领, 周西华, 袁东辉, 等. 参倍固肠胶囊联合奥替溴铵治疗腹泻型肠易激综合征的临床研究[J]. 现代药物与临床, 2021, 36(6): 1165-1170.
[41] 刘瑞娟, 时昭红. 加味葛根芩连汤治疗脾胃湿热型腹泻型肠易激综合征疗效观察[J]. 山西中医, 2021, 37(6): 17-19.
[42] 凌家生, 谭文涛, 林浩, 等. 透邪解毒方治疗胃肠湿热型腹泻型肠易激综合征的临床观察[J]. 中国医学创新, 2021, 18(30): 86-90.
[43] 王平, 谢立群, 魏睦新. 四磨汤口服液治疗便秘型肠易激综合征的临床疗效观察[J]. 广州中医药大学学报, 2019, 36(2): 177-180.
[44] 郭婉薇, 贾林, 许鸣, 等. 六味能消胶囊联合西药治疗便秘型肠易激综合征的临床观察[J]. 湖南中医药大学学报, 2018, 38(9): 1058-1061.
[45] 黄礼, 韦祎, 刘英莲. 麻子仁增液汤对便秘型肠易激综合征患者的临床研究[J]. 世界中医药, 2021, 16(2): 289-293.
[46] 高榆嘉, 张文静, 刘萌, 等. 薄荷药理作用的研究进展[J]. 吉林医药学院学报, 2020, 41(3): 215-217.
[47] Chumpitazi BP, Kearns GL, Shulman RJ. the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders[J]. Aliment Pharmacol Ther, 2018, 47(6): 738-752.
[48] Alammar N, Wang L, Saberi B, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data[J]. BMC Complement Altern Med, 2019, 19(1): 1-10.
[49] Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome[J]. Am J Gastroenterol, 2018, 113: 1-18.
[50] Zheng H, Li Y, Zhang W, et al. Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: a randomized controlled trial[J]. Medicine, 2016, 95(24): e3884.
[51] Pei L, Geng H, Guo J, et al. Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial[J]. Mayo Clin Proc, 2020, 95(8): 1671-1683.
[52] 陈瑞琳, 王洪, 牛柯敏, 等. 肠易激综合征中医外治法研究概况[J]. 北京中医药, 2019, 38(3): 296-299.
[53] 王雅琴, 张瑞春. 中医推拿对治疗肠易激综合征的疗效[J]. 世界最新医学信息文摘, 2018, 18(61): 144-146.
[54] Bu FL, Han M, Lu CL, et al. A systematic review of Tuina for irritable bowel syndrome: recommendations for future trials[J]. Complement Ther Med, 2020, 52: 102504.
[55] 罗钦, 汤善宏, 马鑫, 等. 穴位贴敷治疗肠易激综合征用药及选穴规律分析[J]. 西南军医, 2021, 23(3): 266-270.
[56] 周滔, 谭海成, 杨仲婷, 等. 健脾温肾巴布剂穴位贴敷法治疗脾肾阳虚型腹泻型肠易激综合征临床观察[J]. 中华中医药杂志, 2020, 35(11): 5858-5862.
[57] 洪珍梅, 王樟连, 陈晓军. 穴位埋线治疗腹泻型肠易激综合征疗效观察[J]. 中国针灸, 2011, 31(4): 311-313.
[58] 国家食品药品监督管理总局.总局关于发布中药新药用于肠易激综合征临床研究技术指导原则等5个临床研究技术指导原则的通告(2017年第217号)[EB/OL].(2017-12-27).
https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20171227183101142.html .[59] Lembo A, Weber HC, Farraye FA. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder[J]. Drugs, 2003, 63(18): 1895-1905.
[60] Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome[J]. Scand J Gastroenterol, 2004, 39(2): 119-126.
[61] Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress[J]. Aliment Pharmacol Ther, 1997, 11(2): 395-402.
[62] 唐旭东, 王萍, 刘保延, 等. 基于慢性胃肠疾病患者报告临床结局测量量表的编制及信度、效度分析[J]. 中医杂志, 2009, 50(1): 27-29.
[63] Zung WW. A rating instrument for anxiety disorders[J]. Psychosomatics, 1971, 12(6): 371-379.
[64] Zung WW. A Self-rating depression scale[J]. Arch Gen Psychiatry, 1965, 12: 63-70.
[65] Hamilton M. The assessment of anxiety states by rating[J]. Br J Med Psychol, 1959, 32(1): 50-55.
[66] Hamilton M. A rating scale for depression[J]. J Neurol Neurosurg Psychiatry, 1960, 23(1): 56-62.
-
下载:
计量
- 文章访问数: 653
- 施引文献: 0